C4 Therapeutics, Inc. 8-K

What Happened
C4 Therapeutics, Inc. (CCCC) filed an 8-K on June 24, 2026 reporting the results of its Annual Meeting of Stockholders. Stockholders elected Class III directors Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar to serve until the 2029 annual meeting. Shareholders also cast a non-binding advisory vote to approve executive compensation, ratified KPMG LLP as the company’s independent auditor for 2026, and approved an amendment to the 2020 Stock Option and Incentive Plan to include outstanding pre-funded warrants in the evergreen share-count calculation.

Key Details

• Director election votes (For / Withheld / Broker non-votes):
  • Andrew J. Hirsch: 47,797,964 / 8,247,406 / 21,049,125
  • Stephen Fawell, Ph.D.: 47,811,414 / 8,233,956 / 21,049,125
  • Utpal Koppikar: 46,491,892 / 9,553,478 / 21,049,125
• Say-on-pay (non-binding advisory): For 54,935,574; Against 1,070,926; Abstain 38,870; Broker non-votes 21,049,125.
• Auditor ratification: KPMG LLP ratified — For 76,891,210; Against 185,427; Abstain 17,858.
• 2020 Stock Option and Incentive Plan amendment approved to treat outstanding pre-funded warrants as issued and outstanding shares for calculating the annual evergreen increase (vote: For 33,713,572; Against 22,287,787; Abstain 44,011; Broker non-votes 21,049,125).

Why It Matters
These outcomes confirm management and board continuity (three directors re-elected) and shareholder support for the company’s executive pay proposal. Ratification of KPMG keeps the company’s auditor in place for 2026. The approved amendment to the stock plan’s evergreen provision could increase the pool of shares available for future equity awards by counting pre-funded warrants toward outstanding share totals, which may affect share dilution calculations for investors.